Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gout sufferers could ditch doctor visits with new Self-Monitoring app

NCT ID NCT05507723

Disease control Sponsor: University of Edinburgh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 16, 2026 · Updated 3 times

Summary

This study compares two ways of managing gout: a supported self-management approach where patients monitor their own urate levels with a finger-prick test and adjust medication via a smartphone app, versus usual care where a doctor manages treatment. The goal is to see if the self-monitoring method reduces gout flares over two years. The trial will enroll 125 adults with gout who have had at least one flare in the past year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
urate-lowering medication (e.g., allopurinol) adjusted via self-monitoring
What this could lead to
If successful, this approach could give gout patients a practical way to manage their condition at home, leading to fewer painful flares and better long-term control.
What could go wrong
This is a relatively small trial (125 people) and relies on patients consistently using the app and self-testing, which may not work for everyone. The benefits seen in earlier short-term studies may not hold over two years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 125 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provision of informed consent. * Age ≥18 years. * Patient has sustained at least one flare of gout in the previous 12 months. * Confirmed clinical diagnosis of gout as per ACR/EULAR criteria * Serum urate \>0.36mm/L. * Patient has a smart phone and is able to install GoutSMART application. Exclusion Criteria: * Subject unable to provide consent * Patient on maximum urate lowering therapy or where therapy cannot be escalated further due to intolerance/adverse reaction to either allopurinol or febuxostat. * End stage renal failure/transplant * Current prescription of medication known to interact with xanthine oxidase inhibitors such as azathioprine or mercapto-purine.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gout are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gout

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gout

Contacts and locations

Locations

  • NHS Lothian

    Edinburgh, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.